7 blockbusters: Analysts spotlight 2022’s crop of drugs most likely to win top marketing status — 2 drugs dominate
Every year, the analysts over at Clarivate issue their predictions for which drugs will hit blockbuster status.
Now in its 9th year, they’ve got some drugs — either pending an FDA approval or just won approval, in the case of the asthma treatment tezepelumab — that they think will become blockbusters (i.e. hit $1 billion in annual revenue) in the next five years. By the end of 2026, the analysts are expecting about $16 billion in sales from the top 7 drugs, and the top 2 candidates — both from Eli Lilly — are predicted to have an out-sized bite.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.